Journal Basic Info

  • Impact Factor: 2.709**
  • H-Index: 11 
  • ISSN: 2474-1663
  • DOI: 10.25107/2474-1663
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.

Major Scope

  •  Hormone Therapy
  •  Targeted Therapy
  •  Radiation Therapy
  •  Sarcomas
  •  Chemoprevention
  •  Leukemia
  •  Neoadjuvant Therapy
  •  Gastrointestinal Cancer


Citation: Clin Oncol. 2021;6(1):1793.DOI: 10.25107/2474-1663.1793

High WT1 Expression Associates with Unfavorable Prognosis in Acute Myeloid Leukemia

Shuqi Zhao, Hanzhang Pan, Qi Guo, Wanzhuo Xie, Jie Jin and Jinghan Wang

Department of Hematology, The First Affiliated Hospital, Zhejiang University College of Medicine, China
Department of Nephrology, The First Affiliated Hospital, Zhejiang University, China

*Correspondance to: Jinghan Wang 

 PDF  Full Text Research Article | Open Access


Background: Recently, WT1-specific Chimeric Antigen Receptor (CAR) - T cell has been identified and evaluated in clinical trials of Acute Myeloid Leukemia (AML). However, the clinical impact of Wilms' Tumor 1 (WT1) expression is still unclear. Therefore, we enrolled two cohorts of AML patients to evaluate the prognostic significance.
Methods: We measured WT1 transcript by real-time quantitative PCR in 173 Cytogenetically Normal AML (CN-AML). To assess the prognostic value of WT1 transcript, we classified patients into high and low groups based on the higher quartile of WT1 expression. The independent prognostic value of WT1 expression was investigated in the context of the well-established predictors including white blood cell counts, age, European Leukemia Net genotype (NPM1 mutations and lacking FLT3-ITD
or CEBPA double allele mutations), mutated genes of IDH1, IDH2 and DNMT3A. In addition, the published GSE12417 data was used as an external validation.
Results: High WT1 expressers have the higher levels of white blood cell counts, and higher percentage of FLT3-ITD and NPM1 mutations. Moreover, high WT1 expressions are positively correlated with the adverse overall survival in patients with CN-AML. This result was also validated in the independent cohort of 163 CN-AML patients from the public dataset GSE12417.
Conclusion: We found high WT1 expression is associated with unfavorable overall survival in CNAML patients.


WT1; Acute myeloid leukemia; Prognosis; mRNA

Cite the Article:

Zhao S, Pan H, Guo Q, Xie W, Jin J, Wang J. High WT1 Expression Associates with Unfavorable Prognosis in Acute Myeloid  Leukemia. Clin Oncol. 2021;6:1793..

Search Our Journal

Journal Indexed In

Articles in PubMed

LINGO-1 is a New Therapy Target and Biomarker for Ewing Sarcoma
 PubMed  PMC  PDF  Full Text
NMR Metabolomics in Ionizing Radiation
 PubMed  PMC  PDF  Full Text
View More...

Articles with Grants

Immunohistochemistry Biomarkers in Bladder Cancer: The Old and the New Immunohistochemistry Markers in Bladder Cancer
 Abstract  PDF  Full Text
Achillea fragrantissima: Pharmacology Review
 Abstract  PDF  Full Text
View More...